Cargando…

Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis

Chagas disease is a neglected disease that remains a public health threat, particularly in Latin America. The most important treatment options are nitroimidazole derivatives, such as nifurtimox and benznidazole (BZN). Some studies suggest that for adults seropositive to T. cruzi but without clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciapponi, Agustín, Barreira, Fabiana, Perelli, Lucas, Bardach, Ariel, Gascón, Joaquim, Molina, Israel, Morillo, Carlos, Prado, Nilda, Riarte, Adelina, Torrico, Faustino, Ribeiro, Isabela, Villar, Juan Carlos, Sosa-Estani, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451967/ https://www.ncbi.nlm.nih.gov/pubmed/32804966 http://dx.doi.org/10.1371/journal.pntd.0008529

Ejemplares similares

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study
por: Colantonio, Lisandro D., et al.
Publicado: (2016)

The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America
por: Picado, Albert, et al.
Publicado: (2018)

A new patient registry for Chagas disease
por: Hotez, Peter, et al.
Publicado: (2020)

Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women
por: Carlier, Yves, et al.
Publicado: (2011)

A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease
por: Torrico, Faustino, et al.
Publicado: (2022)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease
por: Fragata-Filho, Abilio Augusto, et al.
Publicado: (2016)

Early detection of left ventricular diastolic dysfunction in Chagas' disease
por: Cianciulli, Tomás F, et al.
Publicado: (2006)

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation
por: Altcheh, Jaime, et al.
Publicado: (2023)

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease
por: Frade, Virgínia Paula, et al.
Publicado: (2022)

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease
por: Parrado, Rudy, et al.
Publicado: (2019)

Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Hepatic changes by benznidazole in a specific treatment for Chagas disease
por: Pavan, Tycha Bianca Sabaini, et al.
Publicado: (2018)

Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
por: Gomes, Daniele Cavalcante, et al.
Publicado: (2023)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
por: Vázquez, Cristina, et al.
Publicado: (2023)

Multi-criteria decision analysis approach for strategy scale-up with application to Chagas disease management in Bolivia
por: Pinazo, Maria-Jesus, et al.
Publicado: (2021)

Use of tissue doppler imaging for the early detection of myocardial dysfunction in patients with the indeterminate form of Chagas disease
por: Cianciulli, Tomás Francisco, et al.
Publicado: (2020)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Results and evaluation of the expansion of a model of comprehensive care for Chagas disease within the National Health System: The Bolivian Chagas network
por: Pinazo, Maria-Jesus, et al.
Publicado: (2022)

Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs
por: Cunha, Eleonora Lima Alves, et al.
Publicado: (2019)

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II superiority clinical trial
por: Molina-Morant, D., et al.
Publicado: (2020)

Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2016)

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy
por: Farani, Priscila Silva Grijó, et al.
Publicado: (2021)

Genetic polymorphism of Trypanosoma cruzi bloodstream populations in adult chronic indeterminate Chagas disease patients from the E1224 clinical trial
por: Ramírez, Juan Carlos, et al.
Publicado: (2021)

Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
por: Olivera, Mario J., et al.
Publicado: (2017)

Congenital Chagas disease: an update
por: Carlier, Yves, et al.
Publicado: (2015)

A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: The Bolivian Chagas Platform
por: Pinazo, Maria-Jesus, et al.
Publicado: (2017)

Correction: Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial
por: Molina-Morant, D., et al.
Publicado: (2023)

Therapy of Chagas Disease: Implications for Levels of Prevention
por: Sosa-Estani, Sergio, et al.
Publicado: (2012)

Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil
por: Ferreira, Ariela Mota, et al.
Publicado: (2016)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
por: Gontijo, Maria Katarine Costa Lucas, et al.
Publicado: (2020)

HIV and Chagas Disease Coinfection, a Tractable Disease?
por: Guidetto, Betiana, et al.
Publicado: (2019)

First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
por: Ramírez, Juan C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9609vrggsk2avinr6e8j36m62p